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The effect of apocynin on motor and cognitive  
functions in experimental Alzheimer’s disease.
Abstract
Scope: We investigated the potential beneficial effect of Apocynin (APO) 
on motor and cognitive functions in experimental Alzheimer’s disease (AD).
Materials and Methods: Experimental AD was induced in rats by 
intraventricular streptozotocin (STZ) injection. Sham group received arti-
ficial cerebrospinal fluid (CSF). Both groups were randomly divided into 
two subgroups. One of the subgroups received intraperitoneal APO for while 
the other had normal saline (NS). The animals were evaluated with rotarod, 
accelerod and Water-Maze tests before and after the treatment. Addition-
ally, biochemical markers of oxidative stress such as malondialdehyde (MDA) 
and reduced glutathione (GSH) were analyzed from brain specimens. Stan-
dard histological evaluation and transmission electron microscopy (TEM) 
were used to evaluate the neural damage.
Results: The difference between STZ+NS in comparison with CSF+NS, 
CSF+APO and STZ+APO were statistically significant on 30 and 40 rpm 
on rotarod test. GSH levels, accelerod and Water-Maze test results were not 
statistically significant between subgroups. However, MDA differences be-
tween STZ+NS in comparison with CSF+NS, CSF+APO and STZ+APO 
were statistically significant. Hemotoxilene eozine staining and TEM results 
showed apocynins protective effect. 
Conclusion: These results indicate that APO can provide neuro-protec-
tive effect for motor but not for cognitive performance in experimental AD.
INTRODUCTION
Inflammation has been shown to play a vital role in the pathophysiol-ogy of the Alzheimer’s disease (AD). Microglial cells are responsible 
for removing the remnants of apoptotic neurons and by doing so they 
induce an inflammatory response against amyloid plaques via oxidative 
stress. This theory claims that oxidative stress is the main damaging 
factor in AD (1, 2, 3). However, antioxidant molecules have not shown 
to demonstrate significant clinical benefits (2, 4). 
Recent researches indicate that AD is a brain-specific form of diabe-
tes (5, 6). Hyperglycemia and hyperinsulinemia are correlated with 
development of AD-related pathology (6, 7). Defective insulin signal-
ing, altered levels and/or abnormal activation of components of the 
insulin signaling pathway, and, more importantly, decreased responsive-
ness to insulin were found in AD (5, 8). In response to infection, trauma 
or abnormal collection of protein aggregates; TNF-a is produced main-
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brain and cerebrospinal fluid. Impaired neuronal insulin 
signaling in AD is connected to that soluble proteins of 
the amyloid-b (Ab) peptide–synaptotoxins accumulate 
in AD and cause insulin receptor substrate-1 inhibition 
through TNF-a activation (9, 10).
Intraventricular STZ effectively blocks insulin recep-
tors, deteriorates the glucose metabolism and leads to 
progressive cognitive impairment. STZ induces free rad-
ical and hydrogen peroxide (H2O2) generation, ATP de-
pletion, DNA damage in insulin secreting cells as well as 
decrement of insulin receptor auto-phosphorylation fol-
lowed by insulin resistance in insulin receptor expressing 
cells (11). In the brain the main mechanism of action is 
the development of oxidative stress, mitochondrial dys-
function and activation of the apoptotic pathway (12). 
Intraventricular STZ injection is one of the most fre-
quently used models of experimental AD (13). 
Apocynin (APO) is a naturally occurring NAPDH 
oxidase inhibitor obtained from the roots of Apocynum 
cannabinum (14). APO was shown to implement its anti-
inflammatory function through the blockage of free 
radical, oxygen ion and peroxide formation. The bio-
chemical basis is the inhibition of NADPH oxidase that 
reduces oxygen to superoxide radical (14, 15). It has dem-
onstrated beneficial effects in different experimental in-
flammatory, neurodegenerative and ischemic brain dis-
eases (16, 17). In this study, we aimed to research the 
effect of APO on STZ-induced experimental AD. 
MATERIALS AND METHODS
Experimental animals
The Ethics Committee approved this study 
(Date:25/11/2013, Protocol number:2013/A-86). Seventy 
(35 male, 35 female) Wistar-Albino rats aged 3–4 months, 
weighting 200–275 grams were used as experimental 
animals (50 experimental and 20 sham). Animals were 
kept under standard conditions according to the guide-
lines of the National Institutes of Health and Helsinki 
Declaration.
Before recruiting to the study all potential animals 
were tested by using rotarod (5 rpm 300 seconds) test. The 
failed animals were replaced by new rats, which passed 
the test. 
Rotarod and accelerod tests
We used the previously published standard protocol 
for the testing (18, 19). Rotamex system 4/8 (Columbus 
Instruments, Columbus, Ohio) was used to assess ani-
mals’ performance. Rotarod test was performed at 5, 10, 
20, 30, and 40 rpm’s for maximum 300 seconds. Accel-
erod test was performed by increasing the speed from 1 
to 79 for 240 and 600 seconds (Picture 1A). 
Water-Maze test
The detailed description of the test has been published 
elsewhere (20). Briefly, the rats were allowed to reach the 
platform for 90 seconds. If an animal could not find the 
platform after 90 seconds it was placed on the platform. 
Then the animals were allowed to stay on the platform for 
15 seconds to memorize its location.  This procedure was 
repeated for four consecutive days. On the fifth day, the 
animals were placed into the pool with underwater plat-
form. A digital camera hanged at the top of the pool re-
corded the animals’ movements. The camera was con-
nected to a computer to record and track animals’ 
movements. The time spent to reach the hidden platform, 
time on the platform, and the distance covered in 90 sec-
onds were recorded (Figure 1B). 
Induction of AD (intraventricular 
injection)
The rats were anesthetized by intraperitoneal 10mg/kg 
xylazine and 75 mg/kg ketamine injections. If needed 
additional anesthetics were given but not exceeding more 
than 20% of the initial dose. 
The technique of ventricular cannulation has been re-
ported elsewhere (21). Briefly, the heads were stabilized on 
the stereotaxic frame (ASI instruments, Istanbul) 5 mm 
above the incisor bar interaural line. Under aseptic condi-
tion a sagittal incision was made. The bregma and sagittal 
sutures were exposed. The trajectory was defined by using 
Cartesian co-ordinate system according to the Paxinos-
Watson stereotaxic atlas (22). Two mini burr holes were 
made on either side. The target point was identified 1.5 
lateral to the midline 0.8 mm posterior to the bregma and 
the depth was 3.5 mm. The experimental group received 
totally 3mg/kg STZ and the control group received 20 μl 
of artificial cerebrospinal fluid (CSF) (Sigma) via Hamil-
tonian syringe (Picture 1C). The time required to induce 
neurodegenerative changes was set for 21 days (21, 23).
Study plan
34 rats (68% from total 50 experimental) and 16 (80% 
from total 20 sham) groups survived the procedure. These 
animals were evaluated by Water-Maze, rotarod and ac-
celerod tests. Two rats from the sham group had proce-
dure related hemiparesis and therefore were excluded 
from the study leaving 14 animals (7 male, 7 female) in 
the sham group (70% from total 20 sham group). In order 
to test the APO efficacy in the worst-case scenario, we 
selected 15 animals (6 male, 9 female) from the experi-
mental group with worst performance results to match 
the sham group. Both groups were randomly divided into 
two subgroups, which eventually received either intra-
peritoneal APO or normal saline. 
CSF+APO and STZ+APO subgroups received 10 mg/
kg intraperitoneally APO for 10 consecutive days (ap-
proximately 2–2.5 cc). Control subgroups – CSF+NS and 
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STZ+NS received the same amount of normal saline in-
traperitoneally. After 10 treatment days, the animals were 
tested by Water-Maze, rotarod and accelerod tests. 
Biochemical and histological 
examination
During sacrification the animals were deeply anesthe-
tized by xylazine and ketamine. Thoracotomy was per-
formed, and blood samples were drawn via intracardial 
route. These blood samples were used for routine bio-
chemical analysis, which included glucose, blood urea 
nitrogen, creatinine, aspartate aminotransferase, alanine 
aminotransferase, sodium, and calcium. The brains were 
carefully dissected. One hemisphere was used for histo-
logical examination and the other was kept at –70°C for 
biochemical analysis. During biochemical evaluation, the 
brain samples were weighted, 10 % phosphate tampon 
(pH 7.4, 50 mM) was added and then homogenated on 
ice bath for 1–2 minutes at 12000 rpm (Ultra Turrax 
Type T25-B homogenizer, IKA Labortechnic, Germany). 
A portion of the homogenate was used to measure MDA 
level. The rest was centrifuged at 5000 rpm for 30 minutes 
at 4 °C. The supernatant was drawn and used to measure 
reduced glutathione (GSH) level.
The brain tissue samples were fixed in 10% formalin 
for 48 hours for histopathological examination. After 
fixation and routine histologic tissue preparation proce-
dures, the cerebral tissue specimens were embedded in 
paraffin blocks. Sections of 6–8 μm thicknesses were pre-
pared using a microtome and stained with hematoxylin 
and eosin (H-E).  Brain sections were examined by a 
Leica DFC 280 light microscope and Leica Q Win Plus 
V3 Image Analysis system (Leica Micros Imaging Solu-
tions, Cambridge, UK) and photographed.
The second part (2x2x2 mm) of the brain tissues was 
processed for transmission electron microscopic examina-
tion (TEM). For that purpose, brain samples were fixed 
in 2.5% glutaraldehyde buffered with 0.2 M NaH2PO4 
+ NaHPO4 (pH 7.2–7.3) and post fixed in 1% OsO4. 
After dehydration whit acetone, brain tissue samples were 
embedded in Araldite CY 212. The ultrathin sections (80 
nm) taken from the araldite blocks using an ultramicro-
tome mounted on copper grids. Ultrathin sections were 
contrasted with uranyl acetate and lead citrate then ex-
amined whit Zeiss Libra 120 TEM (Carl Zeiss Company, 
Oberkochen, Germany) and photographed.
Statistical analysis
For detecting even minor effects, the required sample 
sizes used in this study were identified by using statistical 
power analysis. The sample sizes necessary for a power of 
0.80 were estimated using NCSS software. All data were 
analyzed with a commercially available statistics software 
Figure 1: Picture of rotarod test (A), Water-Maze test (B) , ICV injection (C)
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package (SPSS for Windows v.22.0, Chicago, Ilinois, 
USA). Distributions of the groups were analyzed with the 
Kolmogorov-Smirnov test. The Kruskal-Wallis H test was 
performed for comparison of the groups. After the Krus-
kal-Wallis H test, multivariate comparisons were carried 
out by using Student-Newman-Keules test. The data were 
given as median (min-max). A “P” value of <0.05 was 
considered statistically significant.
RESULTS
Results rotarod and accelerod tests
On initial evaluation, there were striking differences 
between the experimental and sham groups. The differ-
ences reached statistical significance on all tests except for 
accelerod 10 min test (Figure 2). We attributed these results 
to STZ’s detrimental effect on motor and cognitive skills. 
Figure 2. The results of the STZ and sham groups on rotarod and acclererod tests (5 rpm: 300±) Striking differences in performance is due to 
detrimental effect of STZ on cognitive functions (vertical axis shown in seconds). The results of the control group were statistically significant 
compared to the STZ group.
Figure 3. The results of rotarod and accelerod tests. The difference between STZ+NS in comparison with CSF+NS, CSF+APO and STZ+APO 
were statistically significant on 30 and 40 rpm (p<0.05). All other comparisons did not reach statistical significance (vertical axis shown in 
seconds). Higher rotation speed (30 and 40 rpm) revealed significant differences between STZ+NS and CSF+NS, CSF+APO, STZ+APO
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On subgroup analysis, however, the difference between 
STZ+NS in comparison with CSF+NS, CSF+APO and 
STZ+APO were statistically significant on 30 and 40 rpm 
(p<0.05). All other comparisons did not reach statistical 
significance (Figure 3). 
Water-Maze test results
The differences between the experimental and sham 
groups reached the statistical significance on time to ar-
rival to the platform (p<0.001, Figure 4). 
The subgroup analysis showed no statistically signifi-
cant differences between any subgroups (Figure 5).
Brain MDA and GSH results
Blood biochemistry results were within normal limits 
and the differences were statistically non-significant 
across the treatment groups. 
The differences between the brain’s GSH across the 
treat ment groups were not statistically significant. MDA 
Figure 4. The results of the STZ and control groups on Water-Maze test before subdivision to treatment groups. The difference on time to ar-
rival to the platform between the groups reached statistical significance but distance covered in 90 seconds and time spent in the target area did 
not (vertical axis shown in meters for distance covered in 90 second, seconds for time to arrival to the platform, and seconds/1000 for the time 
spent in the target area).
Figure 5. The results of Water-Maze tests. There were no statistically significant differences between all groups on distance covered in 90 seconds, 
time to arrival to the platform, and time spent in the target area (vertical axis shown in meters for distance covered in 90 second, seconds for 
time to arrival to the platform, and seconds/1000 for the time spent in the target area).
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differences between STZ+NS and CSF+NS, CSF+APO 
and STZ+APO and groups reached statistical signifi-
cance (p<0.05) indicating the protective role of the APO 
(Figure 6).
RESULTS OF AMYLOID DEPOSITION AND 
NEURAL DAMAGE
A histologist blinded to treatment groups performed 
the histological examination. Light microscopy examina-
Figure 7. Light microscopy images in brain cortex.
A. CSF+NS. Brain cortex. Normal histological appearance. Neuronal nuclei (arrows), glial cells’ nuclei (arrowheads). H&E. Scale 100 μm. 
B. CSF+APO. Brain cortex. Histological appearance is very similar to normal. Neuronal nuclei (arrows), glial cells’ nuclei (arrowheads). H&E. 
Scale 100 μm. C. STZ+SF. Brain cortex. STZ induced neuronal damage. Pyknotic, heterochromatic, disorganized neuronal nuclei (arrows), 
increased glial cells (arrowheads). H&E. Scale 100 μm. D. STZ+SF. STZ induced neuronal damage. Senile plaque formation in the brain 
cortex (arrow). H&E. Scale 100 μm. E. STZ+APO. Brain cortex. STZ induced damage is partially reversed by APO. Pyknotic, heterochro-
matic, neuronal nuclei (arrows). H&E. Scale 100 μm.
Figure 6. The results of MDA and GSH levels. The differences between the brain’s GSH across the treatment groups were not statistically sig-
nificant. MDA differences between STZ+APO and STZ+NS groups reached statistical significance (p=0.046) indicating the protective role of 
the APO (vertical axis shown in nmol/g for MDA and (nmol/g) for GSH).
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tion of CSF+NS group was normal in histological appear-
ance. Cortical layers were easily indefinable, neuronal 
nuclei were euchromatic and had clear contours (Figure 
7A). Neuronal/glia ratio was normal. Hippocampal gran-
ular and pyramidal neurons showed normal histological 
appearance. Under transmission electron microscopy 
neuronal cells had euchromatic and normally shaped nu-
clei (Figure 8A). Mitochondria were observed as oval 
crystals. Granular endoplasmic reticulum had normal 
ultrastructural appearance. There was an observable neu-
rofilament web between glial cells and the neurons. The 
H-E and TEM findings of the CSF-APO group were 
similar to that of CSF-NS (Figure 7B).
Light microscopy revealed numerous neurons with het-
erochromatic and irregularly shaped nuclei in STZ+NS 
group (Figure 7C and D). Neuron/glia ratio was decreased 
in the cortical areas. In addition, we noticed oval shaped 
necrotic neurons with sharp borders. Neurons in hippo-
campal area, especially pyramidal showed prominent het-
erochromasia, pyknosis, and degeneration. Neurofibriler 
tangles were observed in cortical and hippocampal areas. 
Some neurons had lucent perinuclear area that was inter-
preted as cytoplasmic edema. There were apoptotic neurons 
with piknotic nucleus and dense eosinophilic cytoplasm. 
Lipofuscin was present in some cortical cells. Additionally, 
senile plaques were present in cortical areas. TEM analysis 
in STZ+NS group showed the presence of auto-phago-
somes, some filled with lipofuscin (Figure 8B and C). Ax-
ons and dendrites showed marked decrease in neurofila-
ments reaching total absence in some areas. Some neurons 
had concentration of peripheral chromatin density in ad-
dition to advanced intra-cytoplasmic edema and organelle 
degeneration. Mitochondria showed variable degrees of 
injury and subsequent degeneration in this group with sub-
sequent fusion and formation of Charnoly bodies (Figure 
8D). There was disorganization, loss and degeneration of 
neurofilaments in neuronal soma and in between glial cells. 
Ultrastructural examination showed senile plaques with 
disorganized peripheral fibrils with homogenous center. 
STZ+APO group showed marked decrease in histological 
findings observed in STZ+NS group in both light micros-
copy and TEM (Figure 7E and 8E).
DISCUSSION
Despite intensive research the pathophysiology and 
treatment of AD remains elusive. Recently oxidative stress 
theory has gained interest in the scientific community. 
Oxidative stress has been thought one of the main reason 
that takes over a potential role in the pathogenesis of AD. 
Figure 8. Images obtained from transmission electron microscope.
A. CSF+NS. Normal TEM appearance. Neuronal nucleus (N), dendritic neurofilaments and mitochondrion (arrow), myelinated axon (ar-
rowhead). TEM. Scale 2 μm. B. STZ+NS. STZ induced organelle damage. Increased peripheral chromatin density in neuronal nucleus (N), 
intacytoplasmic edema and organelle degeneration (stars), neurofilament degeneration and loss in axons and dendrites (arrow). TEM. Scale 2 
μm. C. STZ+NS. STZ induced organelle damage. Senile plaque (closed loop), loss of crista in mitochondria (thin arrow), neurofilament de-
generation (thick arrow). TEM. Scale 2 μm. D. STZ+NS. STZ induced organelle damage. Condensation of peripheral chromatin in the 
neuronal nucleus (N). Intra-cytoplasmic edema and organelle degeneration (thick arrows), mitochondrial damage and fusion in early stage of 
Charnoly body formation (thin arrows). TEM. Scale 2 μm. E. STZ+APO. STZ induced damage is partially reversed by APO. Although the 
damage is clearly visible it is not as severe as in STZ+NS group. Neuronal nucleus (N), dendritic neurofilament (thick arrow), myelinated axon 
(arrowhead), mitochondrion (thin arrow). TEM. Scale 2 μm.
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Clinical and also preclinical researches show that neuro-
degenerative diseases such as AD are connected with 
higher levels of oxidative stress biomarkers and by lower 
levels of antioxidant defense biomarkers in the brain (24). 
Our study has been arised by this main topic.
Pradip explained connection between STZ and AD. 
STZ administration through route from intracebroven-
tricular injection produces reduced cognition and in-
creased cerebral aggregated Ab fragments, total tau pro-
tein, and Ab deposits. These changes were accompanied 
with decreased glycogen synthase kinase (GSK-3) alpha/
beta ratio (phosphorylated/total) in the brain. Adminis-
tration of STZ in a rodent’s brain has been shown to pro-
duce neuroinflammation, oxidative stress and biochemical 
alterations, which is considered to be a valid experimental 
model of the early pathophysiological changes in neuro-
degenerative disease. STZ-induced spatial learning deficit 
in Morris water maze test and tau phosphorylation in 
rodent’s brain produces sporadic AD (sAD) like pathol-
ogy (25). For this reason, we selected to STZ-induced rat 
model to investigate protective effects of apocynin on AD.
In recent years, the application of protective agents to 
reduce the effects of endogenous oxidative stress and 
metabolic events related to external factors has been wide-
spread (2, 3, 16, 17, 18, 21, 26, 27, 28). It assumes that 
microglia reaction against amyloid plaques with subse-
quent release of reactive oxygen species is the major dam-
aging factor (20, 29). Neuronal death in return leads to 
additional amyloid deposition and eventually vicious 
cycle repeats itself. Charnoly body has been shown to be 
a universal marker of neuronal damage (30, 31, 32). Char-
noly body is a pre-apoptotic and early biomarker of com-
promised mitochondrial bioenergetics and its observation 
in our animals supports this theory. 
It has been suggested that free radical inhibition might 
be a therapeutic target. A lot of natural products which 
might achieve this mechanism are addressed for the treat-
ment of AD. Besides neuroprotection, these products also 
reveal biological effects that target biochemical pathways 
underlying related signs of AD that include cognitive 
damages, mood and anxiety. (33, 34) Also researches in-
dicated that NADPH oxidase is novel therapeutic targets 
for neurodegenerative disorders. NADPH oxidase seems 
to be specifically significant in the modulation of redox-
sensitive signaling pathways and also has been implicated 
in neuronal dysfunction, degeneration, and neuroinflam-
mation (35, 36). Gao et al. emphasized that if we inhibit 
neuronal NADPH oxidase activity we might treat pa-
tients who suffer from AD (36). For this reason, Apocy-
nin is medicine which has recently gained popularity for 
AD but there is no enough study for this answer. That is 
why we made our study. 
In the literature, we didn’t find any research that AD 
was induced with ICV STZ and treated with IP APO. Lull 
et al have studied chronic oral APO in transgenic mice AD 
model (20). They gave same apocynin treatment as us 
which was 10 mg/kg. Similar to our results the authors 
found decrease in amyloid plaque size and neuro-protective 
effect of APO. The results of the Water maze test however, 
showed no beneficial effect between the groups as in our 
study. In addition to the Water-Maze test, we performed 
rotarod and accelerod tests and found that the APO-treat-
ed mice performed better than control group on 30 and 
40 but not at lower rpm’s. It is probably due to the fact that 
the beneficial effect on motor function is subtle and there-
fore higher rotation speed is required to reveal it.  
Dumont et al. found similar cognitive and histopath-
ological results from the transgenic mouse model of AD 
who took also apocynin treatment and so emphasized that 
APO does not sufficient to ameliorate AD symptoms (37). 
Two animals from the STZ-NS group have died before 
the testing was completed. There were no deaths in other 
groups including (and most importantly) STZ-APO 
group. Although the mortality was not the end-result of 
our study this finding indicates that APO might also af-
fect the mortality. 
Some recent researches about AD were made from 
transgenic mouse models. These researches found that 
although there is a genetic susceptibility to AD in trans-
genic mouse, also there are an increased oxidative stress 
and neurodegenerative pathway which is similar to STZ-
induced models (20, 37, 38). As our histopathological 
results, STZ-induced rat model is a reliable model, which 
might give us information about the motor and cognitive 
dysfunction of AD patients and their treatment. 
APO’s mechanism of action is a matter of controversy 
and has been linked to the inhibition of the reactive oxy-
gen species formation. However, Lull et al found no dif-
ference in NADPH oxidase level between the APO-treat-
ed and control groups suggesting that the beneficial effect 
is independent of anti-oxidative action (20). Our results 
support anti-oxidative action of APO, since it restored the 
MDA level. Similarly Wilkinson et al attributed the pro-
tective role of ibuprofen on AD due to its inhibitory effect 
on NOX-2 (39). Further research is required to clarify the 
benefits of anti-oxidative treatment in AD. 
In conclusion, APO showed beneficial effect on high 
challenge motor but not cognitive skills in STZ-induced 
model of AD. Histological and biochemical evaluations 
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